C5α receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA

Oncotarget

Volumn 7, Issue 51, 2016, Pages 84798-84809

  Kaida, Takayoshi ^a   Nitta, Hidetoshi ^a   Kitano, Yuki ^a   Yamamura, Kensuke ^a   Arima, Kota ^a   Izumi, Daisuke ^a   Higashi, Takaaki ^a   Kurashige, Junji ^a   Imai, Katsunori ^a   Hayashi, Hiromitsu ^a   Iwatsuki, Masaaki ^a   Ishimoto, Takatsugu ^a   Hashimoto, Daisuke ^a   Yamashita, Yoichi ^a   Chikamoto, Akira ^a   Imamura, Takahisa ^a   Ishiko, Takatoshi ^a   Beppu, Toru ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

C5 receptor; CD88; Gastric cancer; RhoA

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; COMPLEMENT COMPONENT C5A;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MKN1 CELL LINE; MKN7 CELL LINE; NUGC3 CELL LINE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; STRESS FIBER; UPREGULATION; CARCINOGENESIS; CELL MOTION; CYTOSKELETON; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; COMPLEMENT C5A; CYTOSKELETON; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, ANAPHYLATOXIN C5A; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; STOMACH NEOPLASMS;

EID: 85007478138     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12656     Document Type: Article

References (50)

1. Cancer Genome Atlas Research, N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513: 202-9. doi: 10.1038/nature13480.
2. Yan, W, Qian L, Chen J, Chen W, Shen B. Comparison of Prognostic MicroRNA Biomarkers in Blood and Tissues for Gastric Cancer. J Cancer. 2016; 7: 95-106. doi: 10.7150/jca.13340.
3. Yasui, W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer. 2005; 8: 86-94. doi: 10.1007/s10120-005-0320-0.
4. Bang, YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-97. doi: 10.1016/s0140-6736(10)61121-x.
5. Ushiku, T, Ishikawa S, Kakiuchi M, Tanaka A, Katoh H, Aburatani H, Lauwers GY, Fukayama M. RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases. Gastric Cancer. 2015. doi: 10.1007/s10120-015-0493-0.
6. Ishimoto, T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011; 19: 387-400. doi: 10.1016/j.ccr.2011.01.038.
7. Wada, T, Ishimoto T, Seishima R, Tsuchihashi K, Yoshikawa M, Oshima H, Oshima M, Masuko T, Wright NA, Furuhashi S, Hirashima K, Baba H, Kitagawa Y, et al. Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia. Cancer Sci. 2013; 104: 1323-9. doi: 10.1111/cas.12236.
8. Espelin, CW, Leonard SC, Geretti E, Wickham TJ, Hendriks BS. Dual HER2 targeting with trastuzumab and liposomeencapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancer. Cancer Res. 2016. doi: 10.1158/0008-5472.CAN-15-1518.
9. Oue, N, Sentani K, Sakamoto N, Yasui W. Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. Cancer Sci. 2015; 106: 951-8. doi: 10.1111/cas.12706.
10. Tanner, M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005; 16: 273-8. doi: 10.1093/annonc/mdi064.
11. Huber-Lang, MS, Sarma JV, McGuire SR, Lu KT, Padgaonkar VA, Younkin EM, Guo RF, Weber CH, Zuiderweg ER, Zetoune FS, Ward PA. Structure-function relationships of human C5a and C5aR. J Immunol. 2003; 170: 6115-24.
12. Klos, A, Wende E, Wareham KJ, Monk PN. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev. 2013; 65: 500-43.
13. Gerard, NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature. 1991; 349: 614-7. doi: 10.1038/349614a0.
14. Smedly, LA, Tonnesen MG, Sandhaus RA, Haslett C, Guthrie LA, Johnston RB, Jr., Henson PM, Worthen GS. Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest. 1986; 77: 1233-43. doi: 10.1172/JCI112426.
15. Nitta, H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K, Kikuchi K, Yamada G, Suzuki K, Honda J, Wilson-Morifuji M, Araki N, Eto M, et al. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res. 2013; 19: 2004-13. doi: 10.1158/1078-0432. CCR-12-1204.
16. Gu, J, Ding JY, Lu CL, Lin ZW, Chu YW, Zhao GY, Guo J, Ge D. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 2013; 81: 259-65. doi: 10.1016/j.lungcan.2013.04.020.
17. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, et al. Autocrine effects of tumor-derived complement. Cell Rep. 2014; 6: 1085-95. doi: 10.1016/j.celrep.2014.02.014.
18. Imamura, T, Yamamoto-Ibusuki M, Sueta A, Kubo T, Irie A, Kikuchi K, Kariu T, Iwase H. Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis. Breast Cancer. 2015. doi: 10.1007/s12282-015-0654-3.
19. Fukata, M, Kaibuchi K. Rho-family GTPases in cadherinmediated cell-cell adhesion. Nat Rev Mol Cell Biol. 2001; 2: 887-97. doi: 10.1038/35103068.
20. Goggs, R, Williams CM, Mellor H, Poole AW. Platelet Rho GTPases-a focus on novel players, roles and relationships. Biochem J. 2015; 466: 431-42. doi: 10.1042/BJ20141404.
21. Halayko, AJ, Solway J. Molecular mechanisms of phenotypic plasticity in smooth muscle cells. J Appl Physiol (1985). 2001; 90: 358-68.
22. Chrzanowska-Wodnicka, M, Burridge K. Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol. 1996; 133: 1403-15.
23. Riedemann, NC, Guo RF, Sarma VJ, Laudes IJ, Huber-Lang M, Warner RL, Albrecht EA, Speyer CL, Ward PA. Expression and function of the C5a receptor in rat alveolar epithelial cells. J Immunol. 2002; 168: 1919-25.
24. Zhang, JX, Zha WS, Ye LP, Wang F, Wang H, Shen T, Wu CH, Zhu QX. Complement C5a-C5aR interaction enhances MAPK signaling pathway activities to mediate renal injury in trichloroethylene sensitized BALB/c mice. J Appl Toxicol. 2016; 36: 271-84. doi: 10.1002/jat.3179.
25. Maeda, Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, Kikuchi K, Imamura T, Eto M. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. Oncol Rep. 2015; 33: 1844-50. doi: 10.3892/or.2015.3800.
26. Allen-Gipson, DS, Floreani AA, Heires AJ, Sanderson SD, MacDonald RG, Wyatt TA. Cigarette smoke extract increases C5a receptor expression in human bronchial epithelial cells. J Pharmacol Exp Ther. 2005; 314: 476-82. doi: 10.1124/jpet.104.079822.
27. Kurihara, R, Yamaoka K, Sawamukai N, Shimajiri S, Oshita K, Yukawa S, Tokunaga M, Iwata S, Saito K, Chiba K, Tanaka Y. C5a promotes migration, proliferation, and vessel formation in endothelial cells. Inflamm Res. 2010; 59: 659-66 doi: 10.1007/s00011-010-0178-4.
28. Czermak, BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, Schmal H, Friedl HP, Ward PA. Protective effects of C5a blockade in sepsis. Nat Med. 1999; 5: 788-92. doi: 10.1038/10512.
29. Jose, PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis. 1990; 49: 747-52.
30. Atkinson, SM, Nansen A, Usher PA, Sondergaard BC, Mackay CR, Friedrichsen B, Chang CC, Tang R, Skov S, Haase C, Hornum L. Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model. Autoimmunity. 2015; 48: 460-70. doi: 10.3109/08916934.2015.1031888.
31. Nitta, H, Shimose T, Emi Y, Imamura T, Ohnishi K, Kusumoto T, Yamamoto M, Fukuzawa K, Takahashi I, Higashi H, Tsuji A, Akagi Y, Oki E, et al. Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes. Med Oncol. 2016; 33: 118. doi: 10.1007/s12032-016-0834-9.
32. Walsh, CT, Stupack D, Brown JH. G protein-coupled receptors go extracellular: RhoA integrates the integrins. Mol Interv. 2008; 8: 165-73. doi: 10.1124/mi.8.4.8.
33. Kakiuchi, M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, Yamamoto S, Tatsuno K, Katoh H, Watanabe Y, Ichimura T, Ushiku T, Funahashi S, et al. Recurrent gainof-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014; 46: 583-7. doi: 10.1038/ng.2984.
34. Wang, K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, Chan KH, Chan AS, Tsui WY, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014; 46: 573-82. doi: 10.1038/ng.2983.
35. Yoon, C, Cho SJ, Aksoy BA, Park DJ, Schultz N, Ryeom SW, Yoon SS. Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells. Clin Cancer Res. 2015. doi: 10.1158/1078-0432.CCR-15-1356.
36. Piao, C, Cai L, Qiu S, Jia L, Song W, Du J. Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration. J Biol Chem. 2015; 290: 10667-76. doi: 10.1074/jbc.M114.612622.
37. Huber-Lang, M, Younkin EM, Sarma JV, Riedemann N, McGuire SR, Lu KT, Kunkel R, Younger JG, Zetoune FS, Ward PA. Generation of C5a by phagocytic cells. Am J Pathol. 2002; 161: 1849-59. doi: 10.1016/S0002-9440(10)64461-6.
38. Huber-Lang, M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006; 12: 682-7. doi: 10.1038/nm1419.
39. Van Lith, LH, Oosterom J, Van Elsas A, Zaman GJ. C5astimulated recruitment of beta-arrestin2 to the nonsignaling 7-transmembrane decoy receptor C5L2. J Biomol Screen. 2009; 14: 1067-75. doi: 10.1177/1087057109341407.
40. Hsu, WC, Yang FC, Lin CH, Hsieh SL, Chen NJ. C5L2 is required for C5a-triggered receptor internalization and ERK signaling. Cell Signal. 2014; 26: 1409-19. doi: 10.1016/j. cellsig.2014.02.021.
41. Chen, NJ, Mirtsos C, Suh D, Lu YC, Lin WJ, McKerlie C, Lee T, Baribault H, Tian H, Yeh WC. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature. 2007; 446: 203-7. doi: 10.1038/nature05559.
42. Spicer, JD, McDonald B, Cools-Lartigue JJ, Chow SC, Giannias B, Kubes P, Ferri LE. Neutrophils promote liver metastasis via Mac-1-mediated interactions with circulating tumor cells. Cancer Res. 2012; 72: 3919-27. doi: 10.1158/0008-5472.CAN-11-2393.
43. Sumichika, H, Sakata K, Sato N, Takeshita S, Ishibuchi S, Nakamura M, Kamahori T, Ehara S, Itoh K, Ohtsuka T, Ohbora T, Mishina T, Komatsu H, et al. Identification of a potent and orally active non-peptide C5a receptor antagonist. J Biol Chem. 2002; 277: 49403-7. doi: 10.1074/jbc.M209672200.
44. Sumichika, H. C5a receptor antagonists for the treatment of inflammation. Curr Opin Investig Drugs. 2004; 5: 505-10.
45. Vergunst, CE, Gerlag DM, Dinant H, Schulz L, Vinkenoog M, Smeets TJ, Sanders ME, Reedquist KA, Tak PP. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford). 2007; 46: 1773-8. doi: 10.1093/rheumatology/kem222.
46. Nitta, H, Murakami Y, Wada Y, Eto M, Baba H, Imamura T. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol Rep. 2014; 32: 1715-9. doi: 10.3892/or.2014.3341.
47. Vadrevu, SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, Riediger L, Manne S, Fairlie DP, Gorczyca W, Almanza O, Karbowniczek M, Markiewski MM. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 2014; 74: 3454-65. doi: 10.1158/0008-5472. CAN-14-0157.
48. Nunez-Cruz, S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, DeAngelis RA, Lambris JD, Coukos G, Scholler N. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia. 2012; 14: 994-1004.
49. Eatock, MM, Schatzlein A, Kaye SB. Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev. 2000; 26: 191-204. doi: 10.1053/ctrv.1999.0158.
50. Washington, K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010; 17: 3077-9. doi: 10.1245/s10434-010-1362-z.